medigraphic.com
ISSN 2594-1518 (Digital)
ISSN 1405-0099 (Impreso)

2008, Número S1

<< Anterior Siguiente >>

Cir Gen 2008; 30 (S1)


Tratamiento quirúrgico de los tumores del estroma gastrointestinal

Torres VS, Medrano GR, González RD

Idioma: Español
Referencias bibliográficas: 29
Paginas: 27-31
Archivo PDF: 128.78 Kb.


RESUMEN

El tratamiento tradicional para los tumores del estroma gastrointestinal (GIST) había sido la resección. No obstante, existen factores histopatológicos, farmacológicos y quirúrgicos que han orillado a los especialistas a considerar a los tratamientos sistémicos (inhibidores de las tirosincinasas) como una buena opción terapéutica compatible con la cirugía, entre ellos, el mesilato de imatinib.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Nishida THS. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Pathol 2000; 15: 1293-1301.

  2. Tran T, Davila JA, ElSerag HB. The Epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gatroenterol 2005; 100: 162-168.

  3. Tryggvason G, Gislason HG, Mafnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003; the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289-293.

  4. Demetri GD, Benjamin R, et al. NCCN Task Force Report: management of patients with gastrointestinal stromal tumor update of the NCCN Clinical Practice Guidelines. J NCCN 2007; 5 (Suppl 2): 51-29.

  5. Goetsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumors in underestimated: results of a nation-wide study. Eur J Cancer 2005; 41: 2868-2872.

  6. Rubio J, Marcos-Gragera, Ortiz MR, et al. Incidence of gastrointestinal stromal tumors (GIST) In Girona, Spain. Eur J Cancer 2007; 43: 144-148.

  7. Nilson B, Bumming P, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical cause and prognostication in the preimatinib mesylate era a population based study in western Sweden. Cancer 2005; 103: 821-829.

  8. DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-KIT), and inhibitor (STI571). Ann Surg Oncol 2002; 9: 831-9.

  9. Agaimy A, Wynsh PH, et al. Minute gastric sclerosing stromal tumors are common in adults an frequently show c-KIT mutations. Am J Surg Phatol 2007; 31: 113-120.

  10. Patel S, Benjamin R. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 2000; 9: 67-70.

  11. Pierie JP, Choudry U, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-9.

  12. Miettinen M, Sobin LH, et al. Gastrointestinal stromal tumors of the stomach: a clinicophatologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Phatol 2005; 29: 52-68.

  13. Miettinen M, Sobin LH, et al. Gastrointestinal tumor of the jejunum and ileum: a clinical a clinicophatologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long term follow-up. Am J Surg Phatol 2006; 30: 477-489.

  14. Pérez EA, Livingstone AS, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202: 623-629.

  15. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Ann Oncol 2005; 16: 566-578.

  16. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.

  17. Demetri G, von Mehren M, Blajke C, el al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.

  18. Dow N, Giblen G, Sobin LH, et al. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol 2006; 23: 11-119.

  19. Chirieac LR, Trent JC, Steiner DM, et al. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 2006; 107: 2237-2244.

  20. Kawanowa K, Sakuma Y, Sakuray S, el al. High incidence of microscopic gastrointestinal stromal tumor in the stomach. Hum Pathol 2006; 37: 1527-1535.

  21. Madeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Phatol 2004; 28: 889-894.

  22. Rothlin M, Schob O. Laparoscopic wedge resection for benign gastric tumors. Surg Endosc 2001; 15: 893-5.

  23. Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointestinal stromal tumor: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-12.

  24. Otani Y, Ohgami M, Igarashi N, et al. Laparoscopic wedge resection of gastric submucosal tumors. Surg Laparos Endos Percutn Thec 2000; 10: 19-23.

  25. Lehnert T. Gastrointestinal sarcoma (GIST a review of surgical management. Ann Chir Gynecol 1998; 87: 297-305.

  26. Margaret von Mehren, Watson JC, et al. Gastrointestinal tumors. Hematol Oncol Clin Am 2005; 19: 547-64.

  27. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.

  28. Eckardt AJ, Wassef W, et al. Diagnosis of subepithelial tumors in the GI tract. Endoscopy, EUS and histology: bronze, silver, and gold standard? Gastrointestinal Endoscopy 2005; 62: 209-212.

  29. Hirota S, Ohashi A, Nishida T, et al. Gain-of function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-7.




2020     |     www.medigraphic.com